STAAR Surgical: China Generates More Than Half Of Q2 Revenue As Total Sales Jump 111%
STAAR Surgical reported Q2 2026 net sales of $93.5 million, up 111% year over year. China generated $52.3 million, over half of revenue. Excluding China, sales rose 6%. Gross margin rose to 74.5% and operating income was $10.1 million. Net income was $8.1 million, or $0.16 diluted EPS.
How this was made
The 30-second read
Why it matters
Traders will likely re-rate STAA on the combination of (1) China’s share gains and mix improvement (toric lenses, EVO+), (2) the swing to operating income, and (3) the credibility of the Switzerland manufacturing plan to mitigate tariffs by end of 2026.
Market read
A detailed Q2 print with China concentration, margin expansion, and a defined tariff-mitigation timeline provides actionable inputs for near-term positioning and 2H26 margin expectations.
What to watch
Tariff pressure is expected to continue until all China-bound products are manufactured in Switzerland by end of 2026, which could cap margin upside even if procedure mix improves.
Background
STAAR’s Q2 growth is framed as a China normalization story after a weak Q2 2025 comparison, alongside improving profitability and product-mix shifts tied to EVO+ adoption.
Ticker impact
STAAR Surgical reported Q2 2026 net sales of $93.5M, up 111% YoY, with China at $52.3M and gross margin rising to 74.5%.
Likely supportive for the stock near term, with traders focusing on whether China share gains and tariff-driven cost headwinds are sustainable into 2H26.
The article provides multiple concrete financial datapoints (sales, margins, operating income, cash) and management commentary on mix (EVO+ adoption, toric lens shift) and a defined manufacturing/tariff mitigation timeline (Switzerland by end of 2026).
Market effects
Strength in ICL procedures versus laser refractive demand could reinforce investor appetite for ophthalmic device makers tied to refractive surgery.
China is the key swing factor, so any follow-through in Chinese distributor inventory and procedure volumes can dominate near-term sentiment.
Tariff and manufacturing localization plans (Switzerland ramp) may affect cost structures for other medtech firms exporting into China.
Counterpoint
The 111% headline growth may overstate underlying demand because the prior-year China base was distorted by minimal EVO ICL shipments and distributor inventory digestion.
Key entities
- companySTAAR Surgical
Reported Q2 2026 net sales, margin expansion, and profitability improvement, with China generating over half of revenue.
- productEVO+
Management attributes China and mix improvements to increased EVO+ adoption and higher ASPs.
- operational factorSwitzerland manufacturing ramp
Gross margin benefited from cost items, while tariff pressures are expected to persist until Switzerland manufacturing is complete by end of 2026.
